Cerenome, Inc.
CNSY
Positions held
Your positionsCNSY isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $13.59M | Enterprise value | $5.04M | Trailing P/E | — | Forward P/E | -0.72 |
| PEG | 2.45 | Price / book | 2.40 | Beta | 1.47 | Dividend yield | 0.00% |
| Revenue growth | -70.4% | Earnings growth | — | Gross margin | -2.0% | Operating margin | -22.0% |
| Profit margin | 0.0% | ROE | -6.1% | ROA | -135.4% | Debt / equity | 0.01 |
| Current ratio | 1.37 | Free cash flow | -$13.97M | Analyst recommendation | strong_buy | Mean target | $27.75 |
| 52w high | $19.00 | 52w low | $1.49 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$9.0M | -$6.9M | -$5.7M | -$4.4M | $5.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.1M | -$7.1M | -$5.7M | -$4.5M | -$1.5M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$22.4M | -$13.0M | -$13.3M | -$20.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$15.3M | -$14.7M | -$13.3M | -$19.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Cerenome Launches CNSide® CSF Molecular Profile Tests
2026-09-30 · Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
2026-09-25 · Cerenome to Hold CNSide® Business Update Call on September 30, 2026
2026-09-16 · Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
2026-09-10 · Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
2026-08-14 · Cerenome Reports Second Quarter 2026 Financial Results and Business Update
2026-08-06 · Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
2026-07-31 · Cerenome Launches as an Integrated CNS Oncology Company
Price (daily)
Full chart · RSI · MACD · patterns